摘要
目的探讨急性非ST段抬高心肌梗死和不稳定型心绞痛患者介入治疗中应用血小板糖蛋白Ⅱb/Ⅲa受体抑制剂(替罗非班)的近期安全性和有效性。方法急性非ST段抬高心肌梗死和不稳定型心绞痛患者164例,随机分为替罗非班组(82例)及对照组(82例),比较2组术后24h和30d的复合终点事件包括死亡、再发心肌梗死和靶血管重建的发生率及出血和可逆性血小板减少等并发症的发生率。结果与对照组相比,应用替罗非班可显著降低急性、亚急性血栓发生率(P<0.05);2组出血并发症发生率差异无统计学意义(P>0.05)。结论PCT术后在常规治疗基础上联用替罗非班,能减少近期心血管事件的发生,并不增加出血事件及血小板减少发生率,证明其在早期冠心病介入治疗中使用安全而有效。
Objective To evaluate the efficacy and safety of platelet glycoprotein Ⅱb/Ⅲa Inhibitor tirofiban in patients with non-ST segment elevation myocardial infarction （ NSTEMI ） or unstable angina pectoris （ uAP ） undergoing pereutaneous coronary intervention （PCI ）. Methods 154 patients with NSTEMI or uAP were randomly divided into two groups administering timfiban （ n = 82 ） and placebo （ n = 82 ） respectively. The end point events were the death,myocardial infarction （ MI） ,and incidence of target vessel revascularization （ TVR） and bleeding as well as reversible thrombopenia. Results Tirofiban could significantly decrease acute and subacute thrombosis （ P 〈 0.05 ）. There was no significant difference in bleeding incidence between the groups （ P 〉 0.05 ）. Conclusion Intravenouse tirofiban may reduce the incidence of cardiological events and not increase the incidence of bleeding and thrombopenia,indicating that it is safe and effective in early coronary PCI treatment.
出处
《中国综合临床》
北大核心
2007年第7期582-584,共3页
Clinical Medicine of China
